Bayer's experimental PET tracer demonstrates accuracy in Phase 3 cardiac amyloidosis trial
Source Summary
Bayer's experimental PET tracer has demonstrated accuracy in a Phase 3 clinical trial for cardiac amyloidosis. The tracer is being evaluated as a diagnostic imaging tool for this heart condition.
Why it matters
Positive Phase 3 results for a diagnostic imaging tracer may advance Bayer's development pathway toward potential regulatory approval and clinical use in cardiac amyloidosis detection.
